Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Matthieu Pannaux"'
Autor:
Reuben Benjamin, Nitin Jain, Marcela V Maus, Nicolas Boissel, Charlotte Graham, Agnieszka Jozwik, Deborah Yallop, Marina Konopleva, Matthew J Frigault, Takanori Teshima, Koji Kato, Floriane Boucaud, Svetlana Balandraud, Athos Gianella-Borradori, Florence Binlich, Ibtissam Marchiq, Sandra Dupouy, Maria Almena-Carrasco, Matthieu Pannaux, Sylvain Fouliard, Eolia Brissot, Mohamad Mohty, Laarni Bonganay, Lorraine Catt, Jackie Chappell, Gary Cheung, Vicky Chu, Kirsty Cuthill, Steven Devereux, Alan Dunlop, Rose Ellard, Farzin Farzeneh, Najeem Folarin, Elka Giemza, Shireen Kassam, Majid Kazmi, Andrea Kuhnl, Jen Lewis, Maria Liskova, Alice Mason, Victoria Metaxa, Ghulam Mufti, Helena Munro, Antonio Pagliuca, Piers Patten, Victoria Potter, Carmel Rice, Adeel Saleem, Robin Sanderson, Orla Stewart, Elias Jabbour, Emily Jones, Hagop Kantarjian, Partow Kebriaei, Kara McGee, William Wierda, Jami Brown, Keagan Casey, Matthew Frigault, Hanno Hock, Richard Mathews, Marcela Maus, Meaghan A McKeown, Thomas Spitzer, Vesselina Toncheva, Elie Azoulay, Sophie Caillat-Zucman, Karine Celli-Lebras, Emmanuelle Clappier, Raphael Itzykson, Jérôme Larghero, Etienne Lengliné, Isabelle Madelaine, Martine Meunier, Florence Rabian, Emmanuel Raffoux, Marie-Thérèse Tremorin, Agnes Bonnin, Anne Daguenel-Nguyen, Remy Dulery, Tounes Ledraa, Florent Malard, Clemence Mediavilla, Anne Vekhoff
Publikováno v:
The Lancet. Haematology. 9(11)
The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immedi
Autor:
Fulvio Di Stefano, Matthieu Pannaux, Anne Correges, Stephanie Galtier, Veronique Robert, Gaelle Saint‐Hilary
Adaptive enrichment designs in clinical trials have been developed to enhance drug developments. They permit, at interim analyses during the trial, to select the sub-populations that benefits the most from the treatment. Because of this selection, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cbf3f88c6722a6435bd7557b8f4d835
http://hdl.handle.net/11583/2965141
http://hdl.handle.net/11583/2965141
Autor:
Gianluca Mastrantonio, Mauro Gasparini, Valentine Barboux, Gaelle Saint-Hilary, Matthieu Pannaux, Veronique Robert
Publikováno v:
Statistics in Medicine. 38:1753-1774
The predictive probability of success of a future clinical trial is a key quantitative tool for decision-making in drug development. It is derived from prior knowledge and available evidence, and the latter typically comes from the accumulated data o
Autor:
Esteban López de Sá, Guy Lerebours, Michel Komajda, Benoit Tyl, Matthieu Pannaux, Aurélie de Montigny, Claire Varin, Jeffrey S. Borer, José Luis López Sendón
Publikováno v:
Circulation. Heart failure. 13(7)
Background: The usefulness of adjudication by central end point committees (CECs) is poorly assessed in heart failure (HF) trials. We aimed to assess its impact on the outcome of the SHIFT trial (Systolic HF Treatment With the If Inhibitor Ivabradine
Autor:
Michael Böhm, Jeffrey S. Borer, Matthieu Pannaux, Luigi Tavazzi, Michel Komajda, Karl Swedberg, Ian Ford
Publikováno v:
European Journal of Heart Failure. 20:1315-1322
Aims: A network meta‐analysis (NMA) of all recommended drug groups for the treatment of heart failure with reduced ejection fraction (HFrEF), including their combinations, was performed to assess the relative efficacy and incremental benefit. Metho
Autor:
Marco Metra, Michel Komajda, Burkert Pieske, Matthieu Pannaux, Fabienne Dominjon, Adriaan A. Voors, Richard Isnard, Michael Böhm, Alain Cohen-Solal, Cécile Henon-Goburdhun, Piotr Ponikowski
Publikováno v:
European Journal of Heart Failure. 19:1495-1503
Aims This randomized, double-blind, placebo-controlled trial assessed whether heart rate (HR) reduction with ivabradine improves cardiac function in heart failure with preserved ejection fraction (HFpEF). Methods and results The prEserveD left ventri
Autor:
Michel, Komajda, Michael, Böhm, Jeffrey S, Borer, Ian, Ford, Luigi, Tavazzi, Matthieu, Pannaux, Karl, Swedberg
Publikováno v:
European journal of heart failure. 20(9)
A network meta-analysis (NMA) of all recommended drug groups for the treatment of heart failure with reduced ejection fraction (HFrEF), including their combinations, was performed to assess the relative efficacy and incremental benefit.A search was m
Autor:
Michel, Komajda, Richard, Isnard, Alain, Cohen-Solal, Marco, Metra, Burkert, Pieske, Piotr, Ponikowski, Adriaan A, Voors, Fabienne, Dominjon, Cécile, Henon-Goburdhun, Matthieu, Pannaux, Michael, Böhm
Publikováno v:
European journal of heart failure. 19(11)
This randomized, double-blind, placebo-controlled trial assessed whether heart rate (HR) reduction with ivabradine improves cardiac function in heart failure with preserved ejection fraction (HFpEF).The prEserveD left ventricular ejectIon fraction ch